A handful of US Food and Drug Administration–approved drugs already have time-of-day recommendations on the label for ...

Investors looking for a ton of value and a place to put some of the gains from the huge technology move should consider these ...

At BMS, he played a leadership role in several successful product launches, including Abilify ®, Atripla ®, Eliquis ®, Plavix ...

The first cross-class fixed-dose combination, Atripla, was developed by Gilead and Bristol–Myers Squibb (BMS), and launched in 2006 in the United States. This once-daily pill containing an NNRTI ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

The drugs included Atripla, Trizivir, Zyprexa and Truvada — a bottle of these averages $1,000. Living in New York City at the time, Costa and his conspirators met with Medicaid beneficiaries at ...

The company gained widespread recognition for its development of antiretroviral drugs for the treatment of HIV/AIDS, ...

Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on May 31. Daina Graybosch ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of ...

Standard ARV treatment for HIV infection is a regimen consisting of a combination of different drug classes. cART suppresses the proliferation of drug-resistant mutant strains by blocking a number ...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of ...